Moderna Inc’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday. “The vaccine is being finished … it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,” Bancel said at the World Economic Forum’s virtual Davos Agenda conference. Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union’s drug regulator, which has expressed doubts about the need for a fourth booster dose.

Source: The Guardian January 17, 2022 17:51 UTC